Loading...
MRK logo

Merck KGaAXTRA:MRK Voorraadrapport

Marktkapitalisatie €59.3b
Prijs aandeel
n/a
1Y23.2%
7D-2.4%
1D-1.2%
Portefeuillewaarde
​
Bekijk

Merck KGaA

XTRA:MRK Voorraadrapport

Marktkapitalisatie: €59.3b

Merck KGaA (MRK) Aandelenoverzicht

Merck KGaA is een wetenschaps- en technologiebedrijf in Duitsland. Meer informatie

Beloningen

Verhandeld tegen 57.3% onder onze schatting van de reële waarde

De winst zal naar verwachting met 8.94% per jaar groeien

Betaalt een betrouwbaar dividend van 1.61%

Risicoanalyse

Geen risico's gedetecteerd voor MRK uit onze risicocontroles.

MRK Community Fair Values

Create Narrative

See what 77 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

View all narratives

Merck KGaA Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Merck KGaA
Historische aandelenkoersen
Huidige aandelenkoers€136.30
52 Week Hoogtepunt€148.65
52 Week Laag€100.70
Bèta0.83
1 maand verandering2.17%
3 maanden verandering15.02%
1 Jaar Verandering23.24%
3 jaar verandering-12.21%
5 jaar verandering-21.64%
Verandering sinds IPO778.84%

Recent nieuws en updates

Narratiefupdate • Jul 06

MRK: Bio-Techne Deal And Life Science Recovery Will Drive Future Upside

Analysts have raised their fair value estimate for Merck KGaA from about €172 to roughly €177. This reflects higher blended price targets, even as they note that the planned Bio-Techne acquisition could justify the richer implied future P/E only in more optimistic scenarios.

Recent updates

Narratiefupdate • Jul 06

MRK: Bio-Techne Deal And Life Science Recovery Will Drive Future Upside

Analysts have raised their fair value estimate for Merck KGaA from about €172 to roughly €177. This reflects higher blended price targets, even as they note that the planned Bio-Techne acquisition could justify the richer implied future P/E only in more optimistic scenarios.
Narratiefupdate • Jun 22

MRK: Life Science Tools Recovery Will Support Future Upside Potential

Analysts recently adjusted their views on Merck KGaA after Street price targets diverged, including a cut to €129 at one firm that now sees a more balanced risk and reward, and a raise to €160 at another firm citing early signs of recovery in life science tools. Analyst Commentary Recent commentary on Merck KGaA reflects a split view, with some bullish analysts highlighting early signs of improvement in key segments such as life science tools, while others see the current share price as broadly aligned with the company's exposure to structural growth drivers.
Narratiefupdate • Jun 06

MRK: Life Science Tools Recovery And Lower AI Risk Will Support Upside

Merck KGaA's updated analyst price target now centers around €160, up from €135, with analysts pointing to cautious optimism around life science tools, a more balanced risk and return profile, and sector wide reassessments of recovery potential and valuation. Analyst Commentary Recent research points to a mixed but generally firming stance on Merck KGaA.
Narratiefupdate • May 23

MRK: Healthcare Resilience And Raised 2026 Guidance Will Support Future Upside

Narrative Update on Merck KGaA Analysts now see fair value for Merck KGaA at about €143, up from roughly €141, reflecting recent price target revisions and views that healthcare could appeal to investors given the current macro backdrop, geopolitical risks, and perceived lower exposure to AI disruption risks. Analyst Commentary Recent research snapshots show a mixed stance on Merck KGaA, with some analysts trimming price targets and others taking a more neutral starting point.
Narratiefupdate • Apr 30

MRK: Healthcare Resilience And Sustainable Solvents Will Support Future Upside

The updated analyst price target for Merck KGaA moves modestly lower to about €141 from around €143, reflecting recent target cuts from firms citing a cautious macro backdrop and sector specific views, while still recognizing potential interest in healthcare as investors weigh geopolitical risk and AI related disruption. Analyst Commentary Recent research on Merck KGaA has focused on recalibrating expectations, with multiple firms trimming price targets and one major house initiating coverage with a neutral stance.
Narratiefupdate • Apr 15

MRK: Reset Expectations And 2026 Guidance Will Shape Future Return Balance

Analysts have trimmed the fair value estimate for Merck KGaA from €127.00 to €112.00, reflecting recent reductions in Street price targets and a more cautious stance on profitability, despite slightly higher modeled revenue growth. Analyst Commentary Recent Street research on Merck KGaA has tilted more cautious, with several bearish analysts cutting price targets and reassessing the risk and reward balance.
Narratiefupdate • Apr 01

MRK: Lower AI Disruption Risk And Margin Resilience Will Support Future Upside

Analysts have trimmed the fair value estimate for Merck KGaA from €187.48 to €172.13 as recent price target cuts and more cautious ratings have offset slightly higher revenue growth and profit margin assumptions, along with a lower future P/E multiple. Analyst Commentary Recent research shows a mixed set of opinions on Merck KGaA, but with some clear pockets of optimism that help frame the trimmed fair value estimate.
Narratiefupdate • Mar 18

MRK: Healthcare Resilience And Limited AI Disruption Will Drive Future Upside

Analysts have trimmed the Merck KGaA fair value estimate from €143.88 to €143.20. This reflects recent cuts to Street price targets in light of a tougher macro backdrop, geopolitical risk and more tempered expectations around sector exposure to AI related disruption.
Narratiefupdate • Mar 04

MRK: Margin Resilience And New TGCT Therapy Will Shape Future Upside

Analysts have lifted their price target on Merck KGaA to €130 from €125, citing slightly stronger assumptions for revenue growth, profit margins and future P/E, even as recent rating changes across the sector keep overall views balanced. Analyst Commentary Recent research on Merck KGaA reflects a split view, with some firms turning more cautious while others highlight steady execution and valuation support.
Narratiefupdate • Feb 18

MRK: Margin Gains And HPC Buildout Will Shape Future Upside Potential

Analysts have raised their price target on Merck KGaA to €130 from €125, citing updated expectations for slightly lower revenue growth, a modestly higher discount rate, and a small uplift in projected profit margin and future P/E assumptions. Analyst Commentary Recent research on Merck KGaA presents a mixed picture, but there is a clear cluster of constructive views around valuation, profitability, and execution.
Narratiefupdate • Feb 03

MRK: Mixed Rating Shifts Will Shape Perceived Balance Of Future Return Potential

Narrative Update: Merck KGaA Analysts have inched their average price target for Merck KGaA up by €5 to €130. This reflects updated views on earnings potential and risk after recent research, including a downgrade at Deutsche Bank and a price target adjustment at Barclays.
Narratiefupdate • Jan 20

MRK: Refined Earnings Outlook Points To Balanced Future Return Potential

Analysts have lifted their fair value estimate for Merck KGaA to €127 from €105, citing updated assumptions for revenue growth, profit margins and future P/E multiples that are broadly in line with recent Street target moves, such as the new €130 level from Barclays. Analyst Commentary The recent move to a €130 price target from €125 sits broadly in line with the updated fair value estimate of €127, which suggests that expectations are being fine tuned rather than reset.
Narratiefupdate • Jan 06

MRK: Future Earnings Power And HPC Expansion May Support Upside

Narrative Update on Merck KGaA Analysts have trimmed their price target for Merck KGaA by €20 to €130, citing updated assumptions that reflect a fair value of €184.63, a discount rate of 4.93%, revenue growth of 5.19%, a profit margin of 16.10%, and a future P/E of 23.44x. Analyst Commentary Recent Street research signals that analysts are reassessing Merck KGaA's valuation framework, with the latest work reflecting a price target of €130 compared with a prior level of €150.
Narratiefupdate • Dec 21

MRK: Future Price Cut Signals Slowing Earnings Momentum Ahead

Analysts have trimmed their price target on Merck KGaA to EUR 130 from EUR 150, reflecting slightly lower long term revenue growth and margin expectations, even as they acknowledge the company's ability to sustain a higher future price to earnings multiple. Analyst Commentary Bearish analysts point to a more challenging backdrop for Merck KGaA, with reduced expectations for long term top line expansion and profitability prompting a reassessment of fair value.
Narratiefupdate • Dec 07

MRK: Margin Strength And AI Deal Will Drive Future Upside

Analysts have trimmed their price target on Merck KGaA, cutting it by EUR 20 to EUR 130 as they factor in slightly softer long term revenue growth assumptions, even though profit margin expectations have improved modestly. Analyst Commentary Analysts are recalibrating their views on Merck KGaA, with the reduced price target reflecting a more measured stance on the company’s medium to long term prospects while acknowledging an improved profitability outlook.
Narratiefupdate • Nov 23

MRK: New Leadership Change And AI Partnership Will Drive Shares Higher

Analysts have modestly lowered their price target for Merck KGaA from €150 to €130. They cite a combination of slightly reduced profit margin forecasts and an increased discount rate, even though there is a small uptick in expected revenue growth.
Narratiefupdate • Nov 03

MRK: Future CEO Appointment Will Support Recovery and Restore Confidence

The analyst price target for Merck KGaA has been reduced from EUR 150 to EUR 130, as analysts cite softer growth expectations and recent earnings disappointments. Analyst Commentary Recent street research reflects a cautious tone among analysts regarding Merck KGaA, with a series of price target reductions and rating adjustments.
Narratiefupdate • Oct 20

Global Biotechnology And Digital Automation Will Drive Future Healthcare

Analysts have trimmed their fair value estimate for Merck KGaA from €147.53 to €145.94. This change reflects a series of recent price target reductions and persistent concerns regarding growth prospects and limited near-term catalysts.
Narratiefupdate • Sep 04

Global Biotechnology And Digital Automation Will Drive Future Healthcare

Merck KGaA's consensus price target remains unchanged at €147.53 as analysts adopt a more neutral stance following disappointing Q2 results, lowered guidance, and reduced near-term growth visibility. Analyst Commentary Disappointing Q2 report and weaker-than-expected operational performance.
Analyse-artikel • Jul 24

We Think Merck KGaA (ETR:MRK) Can Stay On Top Of Its Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
User avatar
Nieuw narratief • Nov 24

AI-Driven Semiconductor Surge Powers Healthcare And Electronics To New Heights

Strong growth in semiconductor solutions and life sciences boosts Merck's Electronics and Process Solutions sectors, positively impacting future revenue and earnings.

Rendement voor aandeelhouders

MRKDE PharmaceuticalsDE Markt
7D-2.4%-2.8%-0.4%
1Y23.2%40.9%-0.8%

Rendement versus industrie: MRK presteerde slechter dan de German Pharmaceuticals -sector, die het afgelopen jaar een rendement van 40.9 % opleverde.

Rendement versus markt: MRK overtrof de German markt, die het afgelopen jaar een rendement opleverde van -0.8 %.

Prijsvolatiliteit

Is MRK's price volatile compared to industry and market?
MRK volatility
MRK Average Weekly Movement4.2%
Pharmaceuticals Industry Average Movement6.0%
Market Average Movement5.4%
10% most volatile stocks in DE Market12.8%
10% least volatile stocks in DE Market2.8%

Stabiele aandelenkoers: MRK heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de German markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van MRK is het afgelopen jaar stabiel geweest.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
166859,077Kai Beckmannwww.emdgroup.com

Merck KGaA is een wetenschaps- en technologiebedrijf in Duitsland. Het is actief in de segmenten Life Science, Gezondheidszorg en Elektronica. Het Life Science segment van het bedrijf biedt instrumenten, chemicaliën en apparatuur voor academische laboratoria, biotech- en farmaceutische fabrikanten en de industriële sector.

Merck KGaA Samenvatting

Hoe verhouden de winst en inkomsten van Merck KGaA zich tot de beurswaarde?
MRK fundamentele statistieken
Marktkapitalisatie€59.26b
Inkomsten(TTM)€2.53b
Inkomsten(TTM)€20.96b
23.4x
Koers/Winstverhouding
2.8x
P/S-verhouding

Is MRK overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
MRK resultatenrekening (TTM)
Inkomsten€20.96b
Kosten van inkomsten€8.61b
Brutowinst€12.35b
Overige uitgaven€9.82b
Inkomsten€2.53b

Laatst gerapporteerde inkomsten

Mar 31, 2026

Volgende inkomensdatum

Aug 06, 2026

Winst per aandeel (EPS)5.82
Brutomarge58.93%
Nettowinstmarge12.08%
Schuld/Eigen Vermogen Verhouding40.4%

Hoe presteerde MRK op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

1.6%
Huidig dividendrendement
38%
Uitbetalingsratio

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/07/17 15:34
Aandelenkoers aan het einde van de dag2026/07/17 00:00
Inkomsten2026/03/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Merck KGaA wordt gevolgd door 42 analisten. 14 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Odile RundquistBaader Helvea Equity Research
Gerhard SchwarzBaader Helvea Equity Research
Charles PitmanBarclays